3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate;
Cl-IB-MECA, 2-chloro-N 6 -(3-iodobenzyl)adenosine-5'-Nmethylcarboxamide; GPCR, G protein-coupled receptor; CP532,903, (2S,3S,4R,5R)-3-amino-5- N-{2-[(3,4-dichlorophenyl) amino]quinolin-4-yl}cyclohexanecarboxamide; NECA, adenosine-5'-N-ethylcarboxamide; PAM, positive allosteric modulator.
INTRODUCTION
Allosteric modulators of G protein-coupled receptors (GPCR) are ligands that interact with a binding site on the receptor that is topologically distinct from the orthosteric site to which the native ligand binds May et al., 2007; Göblyös and IJzerman, 2011) . Binding of an allosteric ligand causes a conformational change that influences the behavior of the receptor in response to its orthosteric ligand. Allosteric modulators can increase (PAM, positive allosteric modulator) or decrease (NAM, negative allosteric modulator) the pharmacological response of orthosteric ligands by modifying their binding affinity and/or their efficacy. Currently, there is great interest in the development of allosteric enhancers of GPCRs, since it is envisioned they will provide therapeutic advantages over conventional orthosteric agonists May et al., 2007; Göblyös and IJzerman, 2011) . For instance, PAMs as therapeutic agents are predicted to produce a better clinical response with fewer side-effects since they modulate responses to an endogenous ligand in tissues in a spatially and temporally specific manner rather than producing wide-spread, persistent receptor activation. Benzodiazepines such as diazepam are a good example of the clinical advantage provided by pharmacological allosterism. These agents, which act as allosteric enhancers of the ion channel-coupled γ-aminobutyric acid (GABA) A receptor, are widely used to treat CNS disorders including anxiety and insomnia. In contrast, direct-acting GABA A agonists have proven to be much less useful due in part to their potential to produce undesirable side-effects. Cinacalcet is the first allosteric modulator of a GPCR to be approved for clinical use. This agent effectively treats certain forms of hyperparathyroidism and functions by allosterically modulating the Ca 2+ -sensing receptor involved in parathyroid hormone release.
Allosteric enhancers for the A 3 adenosine receptor (AR) subtype have recently been identified and characterized including the imidazoquinolinamine derivative N-(3,4-dichlorophenyl)-2-cyclohexyl-1H-imidazo [4,5-c] quinolin-4-amine (LUF6000) and the 2,4-di-substituted quinoline derivative N-{2- [(3,4-dichlorophenyl) amino]quinolin-4-yl}cyclohexanecarboxamide (LUF6096; (Gao et al., 2001; Gao et al., 2002; Göblyös et al., 2006; Gao et al., 2008; Heitman et al., 2009; Kim et al., 2009; Gao et al., 2011) .
These modulators increase the maximal efficacy of orthosteric agonists with the human A 3 AR heterologously expressed in CHO cells, in some assays by over 2-fold. Unlike other related A 3 AR modulators that have been characterized (i.e., 1H-imidazo[4,5-c]quinolin-4-amine (DU124183), in an earlier generation of imidazoquinolinamine series), LUF6000 and LUF6096 increase the maximal efficacy of orthosteric ligands without decreasing potency (Göblyös et al., 2006; Gao et al., 2008; Heitman et al., 2009; Kim et al., 2009; Gao et al., 2011; Göblyös and IJzerman, 2011) . LUF6096, which is structurally similar to LUF6000 differing only by opening of the imidazoquinolinamine heterocyclic ring system to leave an amide bridge in place of the imidazole ring (Figure 1 ), provides greater A 3 AR-selectivity versus the A 1 AR in terms of enhancing activity and exhibits almost negligible orthosteric effects on A 1 , A 2A , and A 3 ARs (Heitman et al., 2009; Göblyös and IJzerman, 2011) .
The production of adenosine is increased substantially in tissues under ischemic conditions due to the breakdown of ATP where it is well-known to provide cytoprotection and to promote tissue repair via a variety of mechanisms involving all four AR subtypes including the A 3 AR (Ely and Berne, 1992; Auchampach and Bolli, 1999; Headrick and Lasley, 2009a) . Local enhancement during ischemia/reperfusion injury using an A 3 AR PAM may be an effective means to magnify the protective actions of adenosine and further minimize tissue injury. In the present study, we have examined whether administration of LUF6096 provides protection against myocardial ischemia/reperfusion injury using a well-established in vivo dog model of infarction (Gross and Auchampach, 1992; Mizumura et al., 1996; Auchampach et al., 2003) .
METHODS

Materials.
Cell culture reagents were purchased from Invitrogen (Carlsbad, CA). penicillin, 100 mg/ml streptomycin, and 400 μg/ml G418 at 37 o C in a humidified environment consisting of room air containing 5% CO 2 (Auchampach et al., 1997a) .
To prepare cell membranes, HEK 293 cells expressing ARs were washed in phosphatebuffered saline followed by homogenization in Tris-HCl buffer (50 mM, pH 7.4) containing 1 mM EDTA and 5 mM MgCl 2 , and then centrifuged at 27,000 x g for 30 min
at 4 o C. Cell pellets were washed twice in the same buffer after which the resultant pellets were re-suspended in 50 mM Tris-HCl buffer containing 10% sucrose and stored at -80 o C. AB-MECA was prepared by radioiodination of precursor AB-MECA using the chloramine-T method and purified by HPLC (Auchampach et al., 1997a ).
Anesthetized dog model of infarction. An established barbital-anesthetized, open-
chest dog model of infarction was employed, as previously described in detail (Gross and Auchampach, 1992; Mizumura et al., 1996; Auchampach et al., 2003) . Dogs were randomly assigned to three experimental groups and subjected to the experimental protocols depicted in Figure of the left carotid artery. LAD coronary artery blood flow was continually measured using a flow probe and regional myocardial blood flow was measured at 30 min into the 60-min occlusion period by the radioactive microsphere technique to assess collateral blood flow (Gross and Auchampach, 1992; Mizumura et al., 1996; Auchampach et al., 2003) . Throughout the ischemia/reperfusion experiments, heart rate was maintained at 150 beats/min by left atrial pacing.
After 3 h of reperfusion, the anatomic area at risk (AAR) and the non-ischemic area were demarcated by staining with Evan's blue dye (Gross and Auchampach, 1992; Auchampach et al., 2003) . The hearts were electrically fibrillated, removed, and prepared for infarct size determination using triphenyltetrazolium chloride staining and regional myocardial blood flow measurements (Gross and Auchampach, 1992; Auchampach et al., 2003) . Infarcted and non-infarcted tissues within the AAR were separated and determined gravimetrically (Gross and Auchampach, 1992; Mizumura et al., 1996; Auchampach et al., 2003) . Regional myocardial blood flow was assessed in the subendocardial, midmyocardial, and epicardial regions of the ischemic and nonischemic regions (Gross and Auchampach, 1992; Mizumura et al., 1996 ; Auchampach , 2003) . Dogs were excluded from the study if subendocardial collateral blood flow was >0.15 ml/min/g or if more than three consecutive attempts were required to convert ventricular fibrillation with low-energy direct current pulses (Gross and Auchampach, 1992; Mizumura et al., 1996; Auchampach et al., 2003) .
Measurement of LUF6096 plasma concentrations by liquid chromatography-mass spectrometry (LC-MS).
Blood was collected into heparinized tubes from the femoral vein in dogs from experimental Group III at the times indicated in Figure 2 . The blood samples were immediately centrifuged (1,000 x g for 10 min at 4 o C), and the plasma was stored at -80 o C until assayed by LC-MS. Samples collected at each time point from all of the dogs in Group III were pooled and assayed in triplicate.
Before analysis, the samples were subjected to a solid-phase extraction procedure as follows. LUF6093 (80 ng), a structural homologue of LUF6096 (see Figure 3) , was added into each plasma sample (1 ml) as an internal standard to normalize for sample recovery. After the addition of ethanol (333 μl) and glacial acetic acid (20 μl), the plasma samples were centrifuged (1,000 g for 10 min at 4 o C) and the supernatant was applied to a C18 Bond Elute SPE cartridge that had been preconditioned with 5 ml of ethanol and 15 ml of deionized water. The cartridges were subsequently washed with 5
x 5 ml of deionized water after which the retained material was eluted with 6 ml of ethyl acetate. The column eluate was dried under a stream of nitrogen, re-dissolved in 400 μl of 100% acetonitrile, and transferred to a sample vial for LC-MS analyses. 
RESULTS
Characterization of the modulatory activity of LUF6096 with the canine A 3 AR.
Since the activity of A 3 AR allosteric modulators have only been assessed with respect to the human A 3 AR (Gao et al., 2001; Gao et al., 2002; Göblyös et al., 2006; Gao et al., 2008; Heitman et al., 2009; Kim et al., 2009; Gao et al., 2011) , we conducted preliminary assays to characterize the modulatory actions of LUF6096 on the canine LUF6096-treated groups (Group II = 3.8 ± 0.5%, Group III = 3.9 ± 0.5%) than in the vehicle-treated group (Group I = 7.2 ± 0.7%). Remarkably, the reduction in infarct size was equivalent in magnitude (~50%) in Group III dogs treated with LUF6096 when it was administered only during the reperfusion phase of the study compared to Group II dogs given two doses of LUF6096. Among the treatment groups, there were no differences with respect to the weight of the left ventricle (data not shown). Importantly, there were also no differences among the 3 experimental groups with respect to the size of the area at risk ( Figure 6A ). Figure 6C illustrates the relationship between infarct size and transmural collateral blood flow measured at 30 min into the occlusion period in the three experimental groups. In the control group (Group I), there was an inverse relationship between infarct size and collateral blood flow. This relationship was shifted downward in a parallel fashion (see Figure 6C ) in Groups II and III, indicating that the smaller infarcts observed in the LUF6096-treated dogs occurred independently of changes in collateral blood flow. Collectively, these data show that treatment with LUF6096 provided protection from ischemia/reperfusion injury and that it was effective at mitigating reperfusion-mediated injury.
Bolus administration of LUF096 at 0.5 or 1.0 mg/kg to the dogs produced no immediate changes in heart rate, arterial blood pressure, left ventricular pressure, or LAD coronary artery blood flow in the anesthetized dogs (data not shown). Table 1 summarizes the hemodynamic data collected throughout the ischemia/reperfusion experiments. There were no significant differences in hemodynamics between any of the treatment groups.
There were also no differences in collateral blood flow within any region of the ischemic 
DISCUSSION
ARs are prime targets for pharmacological manipulation by an allosteric mechanism, since adenosine is produced locally in tissues during hypoxia, ischemia, and tissue injury/inflammation where it functions to reduce cellular injury and to promote tissue repair (Ely and Berne, 1992; Auchampach and Bolli, 1999; Headrick and Lasley, 2009b) . Local enhancement of the actions of adenosine might provide greater benefit compared to orthosteric agonists while avoiding unwanted side effects caused by stimulation of ARs expressed in other tissues May et al., 2007; Göblyös and IJzerman, 2011) . In this study, we found that treatment with LUF6096, a selective PAM of the A 3 AR, significantly reduced infarct size in a barbitalanesthetized dog model of myocardial ischemia/reperfusion injury. LUF6096 produced equivalent cardioprotection whether it was present during ischemia or whether it was present exclusively during the reperfusion phase. Administration of LUF6096 to dogs at a dose of up to 1.0 mg/kg was found to be hemodynamically inert during barbital anesthesia, producing no measureable effects on systemic blood pressure, left ventricular pressure, coronary artery blood flow, or collateral blood flow during the ischemic period. While LUF6096 was found to have a relatively short plasma half-life, the dogs tolerated large doses of the drug resulting in plasma concentrations that were expected to provide a sustained therapeutic effect.
Because of the large size of the dogs, we were not able to administer A 3 AR antagonists to confirm the specificity of LUF6096 in this study. This will have to await further (Auchampach et al., 1997b; Black et al., 2002; Ge et al., 2006; Wan et al., 2008; Ge et al., 2010) . Like orthosteric A 3 AR agonists, LUF6096 was able to reduce infarct size by ~50% and to protect against reperfusion-mediated injury by a mechanism that is unrelated to changes in systemic hemodynamics. The large size of the dog also precludes extensive studies to investigate potential molecular mechanisms by which LUF6096 provides protection from ischemia/reperfusion injury. Earlier studies suggest that A 3 AR activation may promote cell survival by facilitating opening of the K ATP channel in cardiac myocytes and by suppressing the robust inflammatory response that occurs during reperfusion (Auchampach et al., 1997b; Black et al., 2002; Ge et al., 2006; Wan et al., 2008; Ge et al., 2010) .
This article has not been copyedited and formatted. The final version may differ from this version. Although we found that LUF6096 functioned effectively as a PAM of the dog A 3 AR, its pharmacological profile versus the dog receptor was slightly different from that observed previously with the human A 3 AR (Heitman et al., 2009; Göblyös and IJzerman, 2011) .
With the dog A 3 AR using the [ forskolin-stimulated cAMP accumulation) with the human A 3 AR, but that it also increased potency 3-fold (Heitman et al., 2009; Göblyös and IJzerman, 2011) . Based on these findings, it is apparent that the actions of allosteric modulators of the A 3 AR are likely to be species-dependent, similar to that observed previously with orthosteric ligands for this AR subtype (Linden, 1994).
We do not have an explanation for the rapid disappearance of LUF6096 from the plasma in the present study. It is possible that it is rapidly metabolized or excreted without chemical modification. The relatively large apparent volume of distribution of LUF6096 and its high lipophilicity suggest that it might be partitioning into certain tissues or is subject to protein binding. As a consequence, the plasma concentration might not reflect its concentration at the site of action. Considering that A 3 AR PAMs have potential utility in treating chronic inflammatory diseases, it will be important to further study the pharmacokinetic characteristics of LUF6096. Since LUF6096 (2,4-disubstituted quinolone) and LUF6000 (imidazoquinolinamine) are structurally distinct (Heitman et al., 2009; Göblyös and IJzerman, 2011) , it will be interesting to determine the in vivo pharmacokinetic parameters of LUF6000 in future animal studies as well.
In summary, this study represents the first reported efficacy of an A 3 AR PAM in an in vivo experimental animal model of myocardial infarction. Our results demonstrate that LUF6096 is well tolerated in anesthetized dogs and that it is effective at reducing injury caused by myocardial ischemia and reperfusion. This proof-of-concept study supports the possibility that A 3 AR enhancers are effective in treating acute ischemia/reperfusion injury as well as other diseases associated with ischemia, tissue injury, and inflammation. Findings from recent clinical trials with the orthosteric A 3 AR agonist IB-MECA indicate that dosing is limited by hemodynamic side-effects including tachycardia (van Troostenburg et al., 2004) . These actions may be due to A 3 AR activation within the cardiovascular system (Yang et al., 2010) or to non-specific interactions with other AR subtypes (Murphree et al., 2002) . Considering that PAMs function more selectively in a site-and event-specific manner and have the potential to produce fewer adverse effects compared to orthosteric agonists, the allosteric enhancer approach to target the A 3 AR for disease treatment might prove to be superior. 
TABLE 1
Hemodynamic data.
TABLE 2
Regional myocardial blood flow data (ml/min/g).
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